References Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients One-year mortality and consequences of COVID-19 in cancer patients: A cohort study Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management Immunological consequences of JAK inhibition: Friend or foe Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease The janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia Impaired antibody response following the second dose of the BNT162b2 vaccine in patients with myeloproliferative neoplasms receiving ruxolitinib Robust induction of b cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine Origin and function of circulating plasmablasts during acute viral infections Characterization of nanoparticles-based vaccines for COVID-19 Evidence of SARS-CoV-2-Specific memory b cells six months after vaccination with the BNT162b2 mRNA vaccine A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction Antibody responses to SARS-CoV-2 in patients with COVID-19 Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the united kingdom Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: A systematic review and meta-analysis Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 pfizer-BioNTech mRNA vaccination: a systematic review Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review Vaccination in patients with kidney failure: Lessons from COVID-19 Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population Vaccination in the elderly: The challenge of immune changes with aging Protection of BNT162b2 vaccine booster against Covid-19 in Israel Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged ≥60 years Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies mRNA-COVID19 vaccination can be considered safe and tolerable for frail patients Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial Immunogenicity of a heterologous prime-boost COVID-19 vaccination with mRNA and inactivated virus vaccines compared with homologous vaccination strategy against SARS-CoV-2 variants Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity Seroconversion to mRNA SARS-CoV-2 vaccines in hematologic patients Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study